Patient‐centred outcomes for oral showed no clear difference in death (all causes) compared with IV iron (low certainty).
It is very uncertain whether patient‐centred outcomes for oral changes cardiovascular death compared with IV iron (very low certainty).
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
Patient‐centred outcomes for oral may leads to lower type of adverse event: all gastrointestinal adverse effects compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in type of adverse event: infection compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in numbers of non‐dialysis patients needing to commence dialysis compared with IV iron (low certainty).
Patient‐centred outcomes for oral showed no clear difference in number requiring transfusion compared with IV iron (low certainty).
Oral and sublingual immunotherapy may leads to higher increase in the amount of egg that could be tolerated compared with no therapy (low certainty).
Oral and sublingual immunotherapy may leads to higher complete recovery compared with no therapy (low certainty).
Oral and sublingual immunotherapy may leads to higher number of children with mild‐to‐severe adverse events compared with no therapy (low certainty).
Direct oral anticoagulants (DOAC) showed no clear difference in all strokes and systemic embolic events compared with warfarin (moderate certainty).
Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).